Related Experiment Video

Updated: Jun 9, 2026

Immunophenotyping and Cell Sorting of Human MKs from Human Primary Sources or Differentiated In Vitro from Hematopoietic Progenitors
14:30

Immunophenotyping and Cell Sorting of Human MKs from Human Primary Sources or Differentiated In Vitro from Hematopoietic Progenitors

Published on: August 7, 2021

Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome

Gudrun Göhring1, Kyra Michalova, H Berna Beverloo

  • 1Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany.

Blood
|August 31, 2010
PubMed

Insights

Cytogenetic risk factors impact childhood myelodysplastic syndrome outcomes. A structurally complex karyotype, defined by ≥3 aberrations including a structural one, is the strongest predictor of poor prognosis in these young patients.

Area of Science:

  • Pediatric Hematology
  • Cancer Cytogenetics
  • Myelodysplastic Syndromes

Background:

  • Myelodysplastic syndromes (MDS) in children are rare but serious hematologic malignancies.
  • Accurate prognostic markers are crucial for guiding treatment decisions in pediatric MDS.
  • Existing cytogenetic risk stratification may not fully capture prognostic nuances in advanced pediatric MDS.

Purpose of the Study:

  • To identify specific cytogenetic risk factors that predict clinical outcomes in children with advanced myelodysplastic syndrome.
  • To evaluate the prognostic significance of karyotypic complexity, introducing a new definition for 'structurally complex' karyotypes.

Main Methods:

  • Analysis of overall survival data from 192 children prospectively enrolled in European Working Group of Myelodysplastic Syndrome in Childhood studies.
  • Karyotypic complexity was assessed, with 'structurally complex' defined as ≥3 chromosomal aberrations including at least one structural aberration.
  • Cox regression analysis was employed to determine the association between cytogenetic findings and patient prognosis.

Main Results:

  • Patients with ≥3 clonal aberrations, but not structurally complex, showed similar survival to those with normal karyotypes.
  • Monosomal and structurally complex karyotypes were strongly associated with poor prognosis (HR=4.6, P<.01).
  • A structurally complex karyotype without monosomy predicted very short 2-year survival (14%, HR=14.5, P<.01).

Conclusions:

  • The presence of a structurally complex karyotype is the most potent independent prognostic marker for poor outcomes in pediatric advanced myelodysplastic syndrome.
  • This refined definition of karyotypic complexity offers improved risk stratification for children diagnosed with advanced MDS.
  • Further research should integrate these cytogenetic findings into clinical decision-making algorithms for pediatric MDS management.

More Related Videos

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Related Concept Videos

Karyotyping01:17

Karyotyping

Describing the number and physical features of chromosomes can reveal abnormalities that underlie genetic diseases. This description is facilitated by special staining techniques that produce a particular banding pattern on each chromosome. State-of-the-art techniques make this approach even more powerful, enabling the detection of individual genes that cause disease.A Simple Chromosome Staining Technique Provides Valuable Scientific InsightSome genetic diseases can be detected by looking at...
Karyotyping01:17

Karyotyping

Describing the number and physical features of chromosomes can reveal abnormalities that underlie genetic diseases. This description is facilitated by special staining techniques that produce a particular banding pattern on each chromosome. State-of-the-art techniques make this approach even more powerful, enabling the detection of individual genes that cause disease.A Simple Chromosome Staining Technique Provides Valuable Scientific InsightSome genetic diseases can be detected by looking at...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...